Clinical trials: Fibrotic Interstitial Lungs Diseases
Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease
Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial
The OPTIMIZE-ILD-1 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated diagnostic pathway on patients with suspected interstitial lung disease (ILD).
- Conditions
- Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease, Fibrotic Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis (IPF)
- Trial name
- OPTIMIZE-ILD-1 (NCT07482917)
- Testing
- Standard ILD Diagnostic Pathway, Optimized ILD Diagnostic Circuit
- Where
- Spain
- Volunteers
- 92 people
- Sponsor
- Hospital de Granollers
Fibrotic Interstitial Lung Disease
Home-based Pulmonary Rehabilitation and Health Coaching in Fibrotic Interstitial Lung Disease
The purpose of this study is to gather information on the effectiveness of a home-based pulmonary rehabilitation program with health coaching and tele-monitoring for improving patient-reported respiratory-related quality of life…
- Trial name
- NCT05130034
- Testing
- Home-based pulmonary rehabilitation
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Mayo Clinic
Pulmonary Alveolar Proteinosis, COPD
Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality.
- Conditions
- Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia
- Trial name
- GARM-COVID19 (NCT04326036)
- Testing
- Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Black Tie Medical, Inc.
Pulmonary Fibrosis
LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION
Prospective, observational, multicenter study that will evaluate the changes in lung function that patients admitted with SARS-CoV-2 pneumonia will present according to the level of severity at 4, 12, 26 and 52 weeks after…
- Trial name
- INC-CVD-202001 (NCT04409275)
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Lung; Disease, Interstitial, With Fibrosis
Mechanisms of Exertional Dyspnea in Fibrotic Interstitial Lung Disease
Exertional dyspnea is a major source of crippling distress and is the hallmark symptom of fibrotic interstitial lung disease (ILD).
- Trial name
- Dyspnea_ILD (NCT01781793)
- Testing
- Room air, Hyperoxia
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of British Columbia
Lung Disease
Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease
The investigators hypothesise that H2H will result in improved symptom control and quality of life and may be more cost-effective than standard best practice.
- Trial name
- H2H-ILD (NCT01450644)
- Testing
- The Hospital2Home Service
- Where
- 2 sites in United Kingdom
- Volunteers
- 52 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Fibrotic Interstitial Lung Disease
PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial
The fibrotic interstitial lung diseases (fILD) are characterised by lung scarring, distressing breathlessness and poor health-related quality of life.
- Trial name
- PFOX (NCT03737409)
- Testing
- Ambulatory Oxygen Therapy
- Where
- Australia
- Volunteers
- 116 people
- Sponsor
- Monash University
Fibrotic Interstitial Lung Disease
High Intensity Interval Training in Fibrotic Interstitial Lung Disease
The fibrotic interstitial lung diseases (fILD) is a group of debilitating chronic lung conditions that are characterised by scarring of lung tissue, dyspnoea on exertion and significant physical impairment.
- Trial name
- HIIT in fILD (NCT03800914)
- Testing
- High intensity interval training, Traditional pulmonary rehabilitation
- Where
- 4 sites in Australia
- Volunteers
- 131 people
- Sponsor
- Monash University
Fibrotic Interstitial Lung Disease
Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease
Early antifibrotic therapy for f-ILD
- Trial name
- NCT07141810
- Testing
- Antifibrotic drugs (nidanib or pirfenidone)
- Volunteers
- 104 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease
Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial
The OPTIMIZE-ILD-2 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated follow-up pathway on patients with established interstitial lung disease (ILD).
- Conditions
- Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- Trial name
- OPTIMIZE-ILD-2 (NCT07486206)
- Testing
- Standard ILD Follow-Up Pathway, Optimized One-Day ILD Follow-Up Circuit
- Where
- Spain
- Volunteers
- 152 people
- Sponsor
- Hospital de Granollers
Lung Diseases, Interstitial, Fibrosis Lung
Research of Burden of Interstititial Lung Diseases in Turkey
The aim of our study is to investigate the etiological distribution of ILD, epidemiological characteristics of ILD cases such as age, gender, geography, smoking, occupation, economic status, education, and comorbidities.
- Trial name
- RBILD (NCT03995654)
- Where
- Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- Karadeniz Technical University
Lung Diseases, Pulmonary Fibrosis
Diffuse Fibrotic Lung Disease
To determine the effects of cyclophosphamide compared with prednisone, dapsone, or high-dose intermittent 'pulse' therapy with methylprednisolone in patients with idiopathic pulmonary fibrosis.
- Conditions
- Lung Diseases, Pulmonary Fibrosis, Sarcoidosis
- Trial name
- NCT00000596
- Testing
- prednisone, cyclophosphamide, dapsone
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Fibrosis, Lung Fibrosis
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.
- Conditions
- Pulmonary Fibrosis, Lung Fibrosis, Idiopathic Pulmonary Fibrosis, FAP
- Trial name
- FAPIPET (NCT06189820)
- Testing
- FAPI PET/CT
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- Erasme University Hospital
Idiopathic Pulmonary Fibrosis
Dose Reduction and Discontinuation With Anti-Fibrotic Medications
The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.
- Trial name
- NCT05779007
- Testing
- Pirfenidone, Nintedanib
- Where
- United States
- Volunteers
- 2,778 people
- Sponsor
- Boehringer Ingelheim
Interstitial Lung Disease
Specialist Dietetic Intervention in Malnourished Patients with Fibrotic ILD: a Randomised Controlled Pilot Trial
Malnutrition occurs when the body receives too few nutrients, resulting in health problems such as weight loss. The consequences of malnutrition are worrying as they include lung failure, infection, and pressure ulcers.
- Trial name
- DT-ILD (NCT06016959)
- Testing
- Dietetic intervention
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Emphysema, Alveolitis, Fibrosing
Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation
At present, a specific community based rehabilitation programme for lung or heart-lung transplant recipients does not exist. 160 hospitals throughout the United Kingdom (UK) offer pulmonary rehabilitation programmes.
- Conditions
- Emphysema, Alveolitis, Fibrosing, Cystic Fibrosis, Bronchiectasis
- Trial name
- NCT00129350
- Testing
- Pulmonary rehabilitation programme
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Pulmonary Fibrosis
Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic ILD
The ILDnose study a multinational, multicenter, prospective, longitudinal study in outpatients with pulmonary fibrosis. The aim is to assess the accuracy of eNose technology as diagnostic tool for diagnosis and differentiation…
- Trial name
- ILDnose (NCT04680832)
- Testing
- Electronic nose
- Where
- 5 sites in Australia, France and 3 more
- Volunteers
- 600 people
- Sponsor
- Erasmus Medical Center
Pulmonary Fibrosis, Interstitial Lung Disease
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
This is a collaborative study between Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim Pharmaceuticals and up to 9 other clinical centers across the US to determine the effect of nintedanib on slowing the rate of…
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Respiratory Disease
- Trial name
- ENDCOV-I (NCT04619680)
- Testing
- Nintedanib
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Pulmonary Hypertension, Interstitial Lung Disease
Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study
Over time, patients with fibrosing or interstitial lung disease (ILD) can develop high lung blood pressures (pulmonary hypertension), and this is associated with poorer prognosis and survival.
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonia
- Trial name
- B-PHIT (NCT00637065)
- Testing
- Bosentan
- Where
- 3 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Lung Diseases, Interstitial
Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation
The planned study is a prospective cohort interventional study in IPF and PF-ILD patients after initiating anti-fibrotic therapy and pulmonary rehabilitation.
- Trial name
- Actigraphy (NCT05866198)
- Testing
- Actigraph CP Insight Watch
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of South Florida